Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
Open accessThe DOI matches its Crossref record.
Abstract
A 48-year-old woman with chemorefractory metastatic gastric cancer to the liver was treated in a phase I clinical trial with MetMAb, a monoclonal antibody targeting the Met tyrosine kinase receptor. The primary tumor had high MET gene polysomy and evidence for an autocrine production of hepatocyte growth factor, the growth factor ligand of Met. A complete response was obtained that lasted 2 years; the cancer recurred as a peritoneal deposit invading into the transverse colon and a gastrohepatic ligament node. Compassionate use of MetMAb therapy at recurrence achieved a mixed response: a partial response of the two initial lesions but with development of multiple new foci of carcinomatosis. Tissue and serum studies to evaluate the Met signaling pathway correlated with MetMAb treatment response initially and at the time of recurrence. Significance: This research brief is the first to describe a durable complete response obtained with a molecularly targeted monoclonal antibody, MetMAb, to the receptor tyrosine kinase, Met, in a patient with chemorefractory metastatic gastric cancer. It is also the first to report biomarkers that predicted therapeutic response to Met inhibition. Cancer Discovery; 1(7); OF1–OF7. ©2011 AACR. Read the Commentary on this article by Feng and Ma, p. 550 This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
Szász, A. M., Lánczky, A., Nagy, Á., Förster, S., Hark, K., Green, J. E., Boussioutas, A., Busuttil, R., Szabó, A., & Győrffy, B. (2016) · Oncotarget · doi:10.18632/oncotarget.10337 · Cited by 988
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Self-citationTargeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
Self-citationInhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice
Sennino, B., Ishiguro-Oonuma, T., Schriver, B. J., Christensen, J. G., & McDonald, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2160 · Cited by 60
Metadata
- Authors
- Catenacci, D. V. T., Henderson, L., Xiao, S.-Y., Patel, P., Yauch, R. L., Hegde, P., Zha, J., Pandita, A., Peterson, A., & Salgia, R.
- Venue
- Cancer Discovery
- Published
- 2011-12-01
- Volume
- 1
- Issue
- 7
- Pages
- 573-579
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2113760232
- Cited by
- 109
- References
- 0
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. https://app.cochat.ai/papers/10.1158/2159-8290.cd-11-0175
- The paper
- Catenacci, D. V. T., Henderson, L., Xiao, S.-Y., Patel, P., Yauch, R. L., Hegde, P., Zha, J., Pandita, A., Peterson, A., & Salgia, R. (2011). Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-11-0175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.